Debie Hoivik

Debie Hoivik possesses extensive experience in the pharmaceutical industry, having served as Vice President of Early Development and Senior Director of Nonclinical Drug Safety at Akebia Therapeutics from May 2019 to February 2022. Prior to that, Debie worked at Boehringer Ingelheim for over 13 years in roles focused on Nonclinical Drug Safety and Development. Debie's career began at GlaxoSmithKline, where contributions were made in Medicine Safety Evaluation from January 1998 to January 2005. Debie Hoivik earned a Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology from the University of Connecticut and completed a postdoctoral fellowship at Texas A&M University.